Monica Namayanja is the Associate Director, Postgraduate Studies at the Kampala International University – Western Campus (KIU-WC).
Monica is currently pursuing a PhD in Molecular Biology from Makerere University. She holds a Masters Degree in Biotechnology and a Bachelors Degree in Chemistry Botany & Zoo from Barkatulla Vishwavidyalaya University in Bhopal-India. She also holds a Certificate in Immunology in the Tropics from the Makerere UVRI Infection and Immunity Research Training Programme, a Certificate in Intermediate Biostatistics in Epidemiology from the Makerere University College of Health Sciences in Kampala-Uganda, a Certificate in Infections and Brain Dysfunctions (sleep, epilepsy and behaviour) from the Neuro Science Schools in Africa ( sponsored by IBRO), and a Diploma in Office Automation from the Microsoft Institute of Information Technology in Bhopal-India.
From 2005 to 2012, Monica was a Research Fellow at Molecular Biology Laboratory and Part time Lecturer, at the Department of Bio-Molecular and Bio-Lab Sciences, School of Biosecurity, Biotechnical and Laboratory Sciences in the College of Veterinary Medicine Animal Resources and Biosecurity at Makerere University in Kampala-Uganda where she gained knowledge and skills in Immunology Research. She also worked as a visiting Research Associate in USA in 2009 at the Fraunhofer Center for Molecular Biotechnology in Newark-Delaware, where she with the Immunology Department to evaluate the vaccine candidates using techniques such as ELISA, Western blotting, Immunofluorescence assay among others. In 2008, she worked as a visiting Research Associate at in the Neuroscience Department Karolinska Institutet in Stockholm-Sweden
She is qualified in carrying out all manner of experiments on nucleic acids, proteins different type of cells as well as animal related experiments. Her research work aims at unravelling the mechanisms of Trypanosoma brucei-host cell interactions related to the traversal of the blood brain barrier whose results will provide information that will be useful in development of new drugs. In addition to this, the expertise gained from this study can also be used in tackling other diseases. She intends to continue working with Universities or renowned scientific research institutes as a renowned Scientist, coming up with ways of developing research capacity both at infrastructure and human resource level.
Kasozi K. I., Namubiru S.,Safiriyu A.A, Ninsiima H.I., Nakimbugwe D.,Namayanja M., and Betancourt M.B (2018). Amaranth Is Associated with Improved Hepatic and Renal Calcium Metabolism in Type 2 Diabetes Mellitus of Male Wistar Rats.
Evidence-Based Complementary and Alternative Medicine:1-11
Namayanja M., Dai Y., Nerima B., Matovu E., Zhao-Rong L., Lubega G.W., and Zhengjun Chen (2017). Trypanosoma brucei brucei traverses different biological barriers differently and may modify the host plasma membrane in the process.
Experimental Parasitology; 174: 31-41
Namayanja M., Flores R., Nanteza A., Nsadha Z., Eyanu S., Prichard R., Knapp E., Yusibov V. and Lubega G.W. (2010). Increased Interferon gamma levels occur in the cerebral spinal fluid during the chronic phase of Trypanosoma brucei brucei infection in cattle.
American Journal of Tropical Medicine and Hygiene; 83(Supplement 5): 224.(Oral presentation)
Namayanja M.R. (2010). Changes in profile of expressed proteins in Trypanosoma brucei brucei prior to brain invasion during experimental African Trypanosomiasis.
American Journal of Tropical Medicine and Hygiene; 83(Supplement 5): 100.(Poster presentation. ACMCIP Abstract).
Nanteza A., Nsadha Z., Eyanu S.,Namayanja M., Flores R., Knapp E., Prichard R., Yusibov V. and Lubega G.W (2010). Severe organ and tissue abnormalities in Ankole cattle experimentally infected with Trypanosoma brucei brucei.
American Journal of Tropical Medicine and Hygiene; 83(Supplement 5): 148.(presented this on behalf of Nanteza A).
Immunogenic potential of AgPept2 and AgPept5 fragments of Trypanosoma brucei antigenic putative protein T.b.927.4.2070.
Immunotherapeutic potential of anti-Trypanosoma brucei P410 antibodies
Vaccine potential of Trypanosoma brucei Pyroglutamyl peptidase Type I protein
Immunogenic potential of the Trypanosoma brucei pyroglutamyl peptidase Type I (PGP I)
Effect of Thimerrosol and Ivermectin on Trypanosoma brucei brueci growth in vitro
Immunolocalisation of Trypanosoma brucei hypothetical membrane protein Tb 927.5.410
Clinical and Parasitological changes in Ankole cattle experimentally infected with Trypnaosoma bricei brucei UTRO 010291B
Production of rabbit anti-Trypanosoma brucei brucei variant surface glycoprotein antibodies
Production of mouse anti-Trypanosoma brucei brucei GVR35 variable surface glycoprotein antibodies
Production of early and late disease stage antibodies